Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

China flag China · Delayed Price · Currency is CNY
6.81
+0.10 (1.49%)
May 29, 2025, 12:44 PM CST
-16.34%
Market Cap 6.89B
Revenue (ttm) 584.20M
Net Income (ttm) -98.23M
Shares Out 1.03B
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend 0.15 (2.21%)
Ex-Dividend Date Jul 4, 2024
Volume 6,491,550
Average Volume 9,410,650
Open 6.71
Previous Close 6.71
Day's Range 6.66 - 6.83
52-Week Range 5.98 - 8.71
Beta 0.36
RSI 52.51
Earnings Date Aug 25, 2025

About Beijing SL Pharmaceutical

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, develops, produces, and markets genetic engineering and related drugs in the People’s Republic of China and internationally. The company’s finished formulations includes temozolomide; arsenic trioxide; lenalidomide capsules; docetaxel; paclitaxel; recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PE... [Read more]

Sector Healthcare
Founded 1994
Employees 856
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002038
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.